<DOC>
	<DOCNO>NCT00313079</DOCNO>
	<brief_summary>A phase I trial patient relapse refractory leukemia human monoclonal antibody kill B cell acute lymphoblastic leukemia . Trial study safety , pharmacokinetics , anti tumor activity antibody give single agent vincristine .</brief_summary>
	<brief_title>Monoclonal Antibody ( mAb ) 216 With Chemotherapy Adult Relapsed Refractory B-Lineage Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>3.1.1 Age Patients must &gt; = 18 year old time study entry . 3.1.2 Diagnosis 3.1.2.1 Histologic Verification Patients must histologic verification Blineage ALL bone marrow relapse refractory disease unresponsive traditional chemotherapy . 3.1.2.2 For patient WITHOUT prior allogeneic BMT : 1 . Second subsequent bone marrow relapse 2 . Primary refractory marrow disease 3 . M3 marrow ( &gt; 25 % blast ) &gt; 25 % leukemic blast peripheral blood 3.1.2.3 For patient WITH prior allogeneic BMT : 1 . First subsequent bone marrow relapse postBMT 2 . M3 marrow M2 ( &gt; 5 % &lt; 25 % blast ) cytogenetic VNTR confirmation 3.1.3 Confirmation antibody reactivity 3.1.3.1 Patient 's leukemic blast ( peripheral blood marrow ) must document bind mAb 216 vitro ( Teng lab ) 3.1.3.2 Patient 's RBC document NOT express fetal `` '' antigen RBC show NOT bind mAb 216 vitro ( Teng lab ) 3.1.4 Patient Must Not Be Eligible For Therapies Higher Priority 3.1.5 Performance Level ( See Appendix I ) Karnofsky &gt; = 50 % 3.1.6 Life Expectancy Must least 8 week . 3.1.7 Prior Therapy Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . 1 . Myelosuppressive chemotherapy : Must receive within one week entry onto study . 2 . Biologic , include monoclonal antibody : At least 2 week since completion therapy biologic agent include monoclonal antibody . 3 . Hydroxyurea use 72 hour study entry 3.1.8 Organ Function Requirements 3.1.8.1 Bone Marrow Function : 3.1.8.1.1 No hematologic criterion WBC , Hgb platelets 3.1.8.1.2 Patients thrombocytopenia responsive platelet transfusion must uncontrolled bleeding . 3.1.8.2 Adequate Renal Function Defined As : A serum creatinine less equal 2 x normal age 3.1.8.3 Adequate Liver Function Defined As : Total bilirubin &lt; = 2 x upper limit normal ( ULN ) age , SGPT ( ALT ) &lt; = 5 x upper limit normal ( ULN ) age 3.1.8.4 Adequate Cardiac Function Defined As : Shortening fraction &gt; = 27 % echocardiogram , Ejection fraction &gt; = 50 % gate radionuclide study . 3.1.9 Regulatory 3.1.9.1 All patient must sign write informed consent . 3.1.9.2 All institutional ( IRB ) FDA requirement human study must meet . 3.2.1 CNS 3 refractory CNS leukemia 3.2.2 Isolated extramedullary relapse 3.2.3 Uncontrolled infection 3.2.4 Lack mAb 216 binding patient 's leukemic blast vitro 3.2.5 Binding mAb 216 `` '' antigen patient 's erythrocyte</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>